Strategies for Discussing Potential Adverse Effects of Talquetamab in MM

News
Video

Experts discuss best practices for educating patients with multiple myeloma on the adverse effects associated with talquetamab treatment.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
Photo of a woman with her hair in a ponytail in front of a light blue background
Photo of a man with a beard in front of a blue background
Image of a woman wearing a patterned shirt in front of a dark blue background
Photo of a woman wearing a blazer in front of an Oncology Nursing News backdrop
Photo of a woman with dark curly hair wearing a floral shirt
Image of a woman with gray hair on a light blue background
Photo of a woman with a blue border around the image
Image of a woman with dark hair wearing a floral shirt in front of a blurred background
Screenshot of Kiah Purcell, MSN, AGPCNP-BC, in a video call with the frame surrounded by an Oncology Nursing News branded border
Related Content
Photo of a woman undergoing radiation therapy

What Should Oncology Nurses Know About Biology-Guided RT?

Bridget Hoyt
August 4th 2025
Article

Nurses should be familiar with PET scan protocol and what to ask patients with lung and bone cancers before administering biology-guided radiation therapy.

The Vitals

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

Lindsay Fischer
August 4th 2025
Podcast

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Graphic of a person with lung tumors

Q&A: Nursing Considerations From Immune Cell Effector Therapy Experts

Bridget Hoyt
August 4th 2025
Article

2025 ICE-T Conference presenters explain what nurses and APPs should take into account as immune cell effector therapies become more widely used.

Beth Faiman Discusses Recent Changes in Multiple Myeloma Treatment Landscape

Beth Faiman Discusses Recent Changes in Multiple Myeloma Treatment Landscape

Lindsay Fischer
August 4th 2025
Podcast

Beth Faiman, PhD, CNP, discusses reclassifying patients with multiple myeloma, the accelerated approval of teclistamab, and the removal of belantamab mafodotin from the US market.

Image that reads "FDA Approved" resembling a seal of approval

Linvoseltamab Gains FDA Accelerated Approval In R/R Myeloma

Bridget Hoyt
August 4th 2025
Article

The FDA has given accelerated approval to the BiTE, linvoseltamab, for use in the fifth line of therapy for relapsed/refractory multiple myeloma.

Graphic of a leukemia cell

FDA Relaxes REMS, Monitoring Rules for Liso-Cel and Ide-Cel

Chris Ryan
August 4th 2025
Article

The FDA removed REMS and reduced certain monitoring needs for liso-cel and ide-cel in B-cell malignancies.